FTSE falls ahead of Bank rate decision but AstraZeneca and RSA rise

Discussion in 'Market News' started by Lily, Nov 6, 2015.

  1. Lily

    Lily Forum Member

    Aug 29, 2015
    Likes Received:
    Investors nervous about interest rates but positive updates give some support

    Leading shares have fallen back ahead of the Bank of England’s latest rate decision and inflation report, amid concerns that the US will sanction dearer borrowing in December.

    But AstraZeneca and RSA Insurance are bucking the downward trend after well received updates.

    2016 will be a pivotal year in our strategic journey. Looking ahead, however, the continued performance of our growth platforms and upcoming launches will combine with our increasing focus on costs and cash generation to help offset short-term headwinds and return AstraZeneca to sustainable growth.

    AstraZeneca is our top pick in European Pharma, with the promise of a rapidly building tempo of pivotal data (durva, treme, benra, Lynparza) and FDA approvals (Lesinurad, PT003, AZD9291, druva, treme) over the next 12 months.

    Continue reading...

Share This Page

free forex signals